J

Javier O. Valenzuela

Universidad Católica del Norte

Publishes on T-cell and B-cell Immunology, Immune Cell Function and Interaction, Immunotherapy and Immune Responses. 10 papers and 977 citations.

10Publications
977Total Citations

Is this you? Claim your profile.

Add your photo, update your bio, and get notified when your ranking changes.

Top publicationsby citations

Cutting Edge: Type I IFNs Provide a Third Signal to CD8 T Cells to Stimulate Clonal Expansion and Differentiation
Julie Curtsinger, Javier O. Valenzuela, Pujya Agarwal et al.|The Journal of Immunology|2005
Cited by 607Open Access

In this study, we show that IFN-alpha beta can have a direct role in linking innate and adaptive responses by providing the "third signal" needed by naive CD8 T cells responding to Ag and costimulatory ligands. Stimulation of CD8 T cells in the absence of a third signal leads to proliferation, but clonal expansion is limited by poor survival and effector functions do not develop. We show that IFN-alpha beta can provide the third signal directly to CD8 T cells via a STAT4-dependent pathway to stimulate survival, development of cytolytic function, and production of IFN-gamma. Provision of the third signal by either IFN-alpha beta or IL-12 results in regulation of the expression of a number of genes, including several that encode proteins critical for effector function.

The Roles of IL-12 in Providing a Third Signal for Clonal Expansion of Naive CD8 T Cells
Cited by 197Open Access

Stimulation of an effective in vitro or in vivo response by naive CD8 T cells requires three signals: TCR engagement, costimulation/IL-2, and a third signal that can be provided by IL-12. In addition to being required for acquisition of cytolytic function, IL-12 is required for optimal IL-2-dependent proliferation and clonal expansion. In experiments examining in vitro stimulation of naive CD8 T cells, IL-12 is shown to stimulate expression of the IL-2R alpha-chain (CD25) to much higher levels than are reached in response to just TCR and costimulation and/or IL-2. In addition, high CD25 expression is substantially prolonged in the presence of IL-12. As a consequence, the cells proliferate more effectively in response to low levels of IL-2. Examination of adoptively transferred TCR transgenic CD8 T cells responding to peptide Ag confirmed that IL-12 up-regulates CD25 in vivo, even when B7-mediated costimulation is largely blocked. TCR- and IL-2-dependent proliferation of CD8 T cells from mice deficient in CD25 was also found to increase in the presence of IL-12, indicating that CD25 up-regulation is not the only mechanism by which IL-12 increases clonal expansion of the cells. IL-2 and IL-12 both act to increase expression of both CD25 and the IL-12R, thus providing positive cross-regulation of receptor expression. These results suggest that when cross-priming dendritic cells present class I/Ag and costimulatory ligands, and produce IL-12, naive CD8 T cells will begin to produce IL-2 and both receptors will be optimally up-regulated to insure that an effective response is generated.

Cutting Edge: Bcl-3 Up-Regulation by Signal 3 Cytokine (IL-12) Prolongs Survival of Antigen-Activated CD8 T Cells
Cited by 95

Clonal expansion of T cells requires cell division and survival during the proliferative phase of the response. Naive murine CD8 T cells responding to Ag and costimulation undergo an abortive response characterized by impaired clonal expansion, failure to develop effector functions, and long-term tolerance. A third signal provided by IL-12 is required for full expansion, activation, and establishment of memory. The enhanced survival, and thus clonal expansion, supported by IL-12 is not due to increased Bcl-2 or Bcl-x(L) expression; both are maximally activated by signals 1 and 2. In contrast, Bcl-3, recently shown to enhance survival when ectopically expressed in T cells, is increased only when IL-12 is present. Furthermore, examination of Bcl-3-deficient CD8 T cells demonstrates that the increased survival caused by IL-12 depends upon Bcl-3. The time courses of expression suggest that Bcl-2 and Bcl-x(L) promote survival early in the response, whereas Bcl-3 acts later in the response.

PKCθ is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice
Javier O. Valenzuela, Cristina Iclozan, Mohammad Salim Hossain et al.|Journal of Clinical Investigation|2009
Cited by 78Open Access

When used as therapy for hematopoietic malignancies, allogeneic BM transplantation (BMT) relies on the graft-versus-leukemia (GVL) effect to eradicate residual tumor cells through immunologic mechanisms. However, graft-versus-host disease (GVHD), which is initiated by alloreactive donor T cells that recognize mismatched major and/or minor histocompatibility antigens and cause severe damage to hematopoietic and epithelial tissues, is a potentially lethal complication of allogeneic BMT. To enhance the therapeutic potential of BMT, we sought to find therapeutic targets that could inhibit GVHD while preserving GVL and immune responses to infectious agents. We show here that T cell responses triggered in mice by either Listeria monocytogenes or administration of antigen and adjuvant were relatively well preserved in the absence of PKC isoform theta (PKCtheta), a key regulator of TCR signaling. In contrast, PKCtheta was required for alloreactivity and GVHD induction. Furthermore, absence of PKCtheta raised the threshold for T cell activation, which selectively affected alloresponses. Most importantly, PKCtheta-deficient T cells retained the ability to respond to virus infection and to induce GVL effect after BMT. These findings suggest PKCtheta is a potentially unique therapeutic target required for GVHD induction but not for GVL or protective responses to infectious agents.

The role of PKC-Theta in CD8 T cell activation (B28)
Javier O. Valenzuela, Xingyu Wang, Sofia Hussain et al.|The Journal of Immunology|2007
Cited by 0

Abstract Protein kinase C- Theta (PKC𝛉) is known to be a key mediator of NF-κB activation downstream of TCR signaling. However, recent in vivo studies with PKC𝛉−/− mice have generated conflicting results regarding its role in T cell activation. To elucidate the role of PKC𝛉 in the activation of CD8 T cells, we generated ovalbumin (ova)-specific PKC𝛉−/− OT1 mice. Stimulation of PKC𝛉−/− OT1 CD8 T cells with microspheres coupled to H2Kb-ova demonstrated a critical function for PKC𝛉 in TCR-induced NF-κB activation and proliferation in vitro. In contrast, ova-induced proliferation and CTL generation in vivo was virtually the same as WT cells. In addition, PKC𝛉−/− CD8 T cells stimulated in vitro with ova-pulsed DC proliferated vigorously and to a similar extent as WT cells. Remarkably, comparable levels of NF-κB were activated in WT and PKC𝛉−/− T cells after stimulation with DC. Proliferation of PKC𝛉−/− cells is severely reduced when DC deficient for B7-1/2 are used to stimulate the cells. Costimulation provided by CD27L also plays a role, as demonstrated by the use of a specific blocking antibody. In contrast to the response against antigen, GVHD responses are severely impaired in the absence of PKC𝛉. These results suggest that impaired TCR/antigen-induced NF-κB activation in PKC𝛉−/− CD8 T cells does not have a significant impact on T cell proliferation when other non-TCR signaling pathways are able to induce NF-κB and T cell activation.